Global expansion of Idorsia's QUVIVIQ continues with EMS partnership for Latin America

Core Viewpoint - Idorsia Ltd has entered into an exclusive license and supply agreement with EMS S.A. to commercialize QUVIVIQ™ (daridorexant) in Latin America, marking a significant step in the company's global expansion strategy [2][3]. Company Overview - Idorsia Ltd is focused on developing transformative medicines and aims to challenge existing medical paradigms [15][16]. - EMS S.A. is Brazil's largest privately-owned pharmaceutical company, with over 60 years of history and a strong market presence [13][14]. Product Information - QUVIVIQ is an innovative treatment for insomnia that selectively blocks orexin receptors, promoting restorative sleep without broadly suppressing brain activity [5][6]. - Clinical trials have shown that daridorexant significantly improves sleep onset, maintenance, and daytime functioning compared to placebo [6]. Market Potential - Insomnia affects millions in Latin America, with current treatments often leading to next-day drowsiness and dependence, indicating a clear unmet need for safer alternatives [4][11]. - The partnership with EMS is expected to enhance the availability of QUVIVIQ in Latin America, addressing the significant demand for effective insomnia treatments [3][7]. Financial Aspects - Idorsia is set to receive a total milestone compensation of USD 20 million for the execution of the agreement, along with supply prices and double-digit royalties on net sales in Brazil and Mexico [10].